Table 4.

 Incidence of cervical intraepithelial neoplasia grade II or grade III or worse after three years of follow-up, stratified by age and recruitment cytology

Outcome and subgroup	Biopsy and recall			Immediate large loop excision		Relative risk* (95% CI)	P value
	No (%) of cases	Cumulative incidence		No (%) of cases	Cumulative incidence
Cervical intraepithelial neoplasia grade II or worse
Age (years):
20-29	134 (31)	116		137 (32)	117	1.01 (0.80 to 1.29)	0.904
30-59	82 (14)	52		91 (16)	59	1.07 (0.79 to 1.44)	0.657
Cytology†:
Mild dyskaryosis	129 (36)	134		120 (35)	125	0.90 (0.70 to 1.16)	0.424
Borderline nuclear abnormalities	87 (14)	49		108 (17)	61	1.24 (0.94 to 1.65)	0.132
Cervical intraepithelial neoplasia grade III or worse
Age (years):
20-29	69 (16)	60		69 (16)	59	0.99 (0.71 to 1.38)	0.950
30-59	38 (7)	24		44 (8)	28	1.10 (0.71 to 1.70)	0.673
Cytology‡:
Mild dyskaryosis	67 (19)	69		59 (17)	62	0.84 (0.59 to 1.19)	0.332
Borderline nuclear abnormalities	40 (6)	23		54 (8)	31	1.35 (0.90 to 2.04)	0.146

*Comparison for immediate large loop excision v biopsy and recall (reference group). Adjusted for age (20-29, 30-39, 40-49, 50-59, as appropriate), recruitment cytology (mild dyskaryosis, borderline nuclear abnormalities, as appropriate), centre (Grampian, Tayside, Nottingham), and high risk human papillomavirus status (positive, negative, unknown).

†Result of cytology test that triggered recruitment into trial; women might have had up to one additional smear showing borderline nuclear abnormalities in previous three years.